Dr. Reddy's Laboratories Ltd ADR (RDY)

Nov 28, 2024, 6:15 AM EST - 7 weeks ago

Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma

Nov 26, 2024, 8:07 AM EST - 7 weeks ago

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market

Nov 5, 2024, 1:26 PM EST - 2 months ago

Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript

Nov 5, 2024, 9:59 AM EST - 2 months ago

Dr. Reddy's Q2 & H1FY25 Financial Results

Oct 25, 2024, 7:40 AM EDT - 3 months ago

Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year

Oct 14, 2024, 9:47 AM EDT - 3 months ago

Dr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month

Oct 8, 2024, 11:32 AM EDT - 3 months ago

Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma

Oct 2, 2024, 11:10 AM EDT - 3 months ago

Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Aug 20, 2024, 2:42 PM EDT - 5 months ago

Dr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial Drug

Aug 13, 2024, 1:33 AM EDT - 5 months ago

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Jul 30, 2024, 8:25 PM EDT - 6 months ago

Dr. Reddy's Laboratories: India 'will be our number one market'

Jul 29, 2024, 11:55 AM EDT - 6 months ago

Dr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab Biosimilar

Jul 27, 2024, 9:51 AM EDT - 6 months ago

Dr. Reddy's Q1FY25 Financial Results

Jun 26, 2024, 11:26 AM EDT - 7 months ago

Dr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare Business

Jun 3, 2024, 1:05 PM EDT - 8 months ago

Aurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing Capabilities

May 28, 2024, 9:53 AM EDT - 8 months ago

Dr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North America

May 21, 2024, 10:05 AM EDT - 8 months ago

Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK

May 7, 2024, 2:42 PM EDT - 9 months ago

Dr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call Transcript

May 7, 2024, 10:31 AM EDT - 9 months ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 3, 2024, 8:00 AM EDT - 9 months ago

Dr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.

Mar 19, 2024, 7:00 AM EDT - 10 months ago

Dr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UK

Feb 13, 2024, 8:25 AM EST - 1 year ago

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

COYA

Jan 31, 2024, 9:44 AM EST - 1 year ago

Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 30, 2024, 3:50 PM EST - 1 year ago

Dr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call Transcript

Jan 3, 2024, 6:00 AM EST - 1 year ago

Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of Brands

Dec 14, 2023, 7:49 AM EST - 1 year ago

Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index

Dec 6, 2023, 7:00 AM EST - 1 year ago

Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)

COYA

Dec 5, 2023, 4:41 AM EST - 1 year ago

India's Dr. Reddy's R&D centre being inspected by US FDA

Oct 27, 2023, 2:48 PM EDT - 1 year ago

Dr Reddy's Laboratories Ltd (RDY) Q2 2024 Earnings Call Transcript

Oct 27, 2023, 2:23 PM EDT - 1 year ago

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27, 2023, 1:50 PM EDT - 1 year ago

Dr. Reddy's Q2 FY24 Financial Results

Aug 23, 2023, 5:02 PM EDT - 1 year ago

Dr. Reddy's: Growth Supported By New Labels, Profitability

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.

Jul 26, 2023, 5:00 PM EDT - 1 year ago

Dr Reddy's Laboratories Ltd (RDY) Q1 2024 Earnings Call Transcript

Jul 26, 2023, 12:31 PM EDT - 1 year ago

Dr. Reddy's Q1 FY24 Financial Results

Jul 12, 2023, 10:25 AM EDT - 1 year ago

Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA

Jun 7, 2023, 7:34 AM EDT - 1 year ago

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Jun 5, 2023, 7:00 AM EDT - 1 year ago

Dr. Reddy's Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab

May 11, 2023, 2:28 AM EDT - 1 year ago

Dr Reddy's Laboratories Ltd (RDY) Q4 2023 Earnings Call Transcript

May 10, 2023, 11:43 AM EDT - 1 year ago

Dr. Reddy's Q4 & FY23 Financial Results

May 8, 2023, 12:29 PM EDT - 1 year ago

Dr. Reddy's: A Profitable, Predictable Margin Expander

May 5, 2023, 7:17 AM EDT - 1 year ago

Dr. Reddy's Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Apr 21, 2023, 7:15 AM EDT - 1 year ago

Dr. Reddy's Laboratories Announces the Launch of Treprostinil Injection in the U.S.

Mar 20, 2023, 7:00 AM EDT - 1 year ago

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy's Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases

COYA

Feb 27, 2023, 6:00 AM EST - 2 years ago

Dr. Reddy's Laboratories Announces Agreement to Acquire Mayne Pharma's U.S. Generic Prescription Product Portfolio

Feb 16, 2023, 7:31 AM EST - 2 years ago

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Feb 8, 2023, 8:50 AM EST - 2 years ago

Dr. Reddy's included in Bloomberg Gender-Equality Index for the 6th year in a row and S&P Global's Sustainability Yearbook for the 3rd year

Jan 27, 2023, 7:03 AM EST - 2 years ago

Dr. Reddy's Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Jan 25, 2023, 2:26 PM EST - 2 years ago

Dr. Reddy's Laboratories Limited (RDY) Q3 2023 Earnings Call Transcript

Jan 20, 2023, 6:30 AM EST - 2 years ago

Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe